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Botswana has a high burden of cervical cancer due to a limited screening program and 
high HIV prevalence. About 60% of the cervical cancer patients are HIV positive; most 
present with advanced cervical disease. Through initiatives by the Botswana Ministry 
of Health and various strategic partnerships, strides have been made in treatment of 
pre-invasive and invasive cancer. The See and Treat program for cervical cancer is 
expanding throughout the country. Starting in 2015, school-going girls will be vaccinated 
against HPV. In regards to treatment of invasive cancer, a multidisciplinary clinic has been 
initiated at the main oncology hospital to streamline care. However, challenges remain 
such as delays in treatment, lack of trained human personnel, limited follow-up care, and 
little patient education. Despite improvements in the care of pre-invasive and invasive 
cervical cancer patients, for declines in cervical cancer-related morbidity and mortality to 
be achieved, Botswana needs to continue to invest in decreasing the burden of disease 
and improving patient outcomes of patients with cervical cancer.
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iNTRODUCTiON
Cervical cancer is the second most common cancer in women in 
low- and middle-income countries (LMICs), with an estimated 
530,000 new cases each year. More than 270,000 women die from 
cervical cancer annually, with >85% of these deaths occurring in 
LMICs. Botswana, a former British protectorate in Sub-Saharan 
Africa, is primarily an English speaking democracy of 2 million 
people with a stable political environment. Within Botswana, cer-
vical cancer is the leading cause of cancer death. More than two-
thirds of cases occur in HIV-infected women (1), with a national 
HIV prevalence of 17–24% in 2013 (2)1,2. Between 2003 and 2011, 
cervical cancer accounted for 14% of all cancers in Botswana and 
26% of all the cancers in women, and the mean age at presentation 
was 52 years. Over 250,000 women in Botswana are in the age 
group 30–49 years about 25% of total female population (2) and 
are, thus, at high risk of developing cervical cancer3. Among this 
subset of women, the HIV prevalence rate approaches 50%. The 
number of women at-risk of cervical cancer will continue to grow 
until effective primary prevention efforts are established (3).
Several strategic partnerships and initiatives over the last 
decade have played a pivotal role in making cervical cancer 
prevention a national priority in Botswana. The main catalyst 
for these collaborations has been the cervical cancer prevention 
pilot program funded by the President’s Emergency Plan for 
AIDS Relief (PEPFAR). Over the last 5 years, data from this pilot 
program have informed national cancer prevention policy (4), 
and guided the Ministry of Health’s (MOH) ambitious plan to 
provide comprehensive, organized cervical cancer prevention 
services nationally3.
The purpose of this piece is to provide an overview of current 
situation of cervical cancer screening and treatment programs 
in Botswana, to describe successes and challenges of the cervi-
cal cancer programs and highlight partnerships that have been 
significant to development of cervical cancer screening and treat-
ment programs in Botswana.
SCReeNiNG
Organized screening, public awareness, and early treatment 
of pre-cervical cancer lesions have led to the relatively low 
incidence of cervical cancer in high-income countries (5). The 
high incidence and mortality rate from cervical cancer in LMICs 
could be reduced by effective screening and treatment programs 
(6)4. Cytology testing using Pap smear has been the mainstay 
of screening in high-income countries (7); however, use of 
cytology screening in LMICs has proven difficult given limited 
1 Botswana S. Preliminary Results Botswana AIDS Impact Survey IV (BAIS IV) 2013 
(2013). 
2 HIV and AIDS Estimates [Webpage] (2013). Available from: http://www.unaids.
org/en/regionscountries/countries/botswana
3 Five-year comprehensive preventions and control strategy (2012-2016). In: 
National Cervical Cancer Prevention Program. Republic of Botswana Ministry of 
Health (2012).
4 Human papilloma and cervical cancer. In: Fact Sheet (2013). Available from: 
http://www.who.int/mediacentre/factsheets/fs380/en/
resources for pathology review with resultant delays in diagnosis 
and limited treatment access leading to disease progression (8, 
9). The Government of Botswana has recognized the burden of 
disease that cervical cancer poses, and, as a result, for the last two 
decades, has attempted to provide screening in the form of cytol-
ogy. Unfortunately, these programs have had a limited impact on 
cervical cancer incidence and mortality due to challenges with 
follow-up, as well as pathological and treatment capacity in a 
setting where screening results are positive for a high proportion 
of women.
“See and Treat” (SAT) screening, as an alternative to cytology, 
is performed through visual inspection after acetic acid (VIA) 
application to the cervix followed by immediate treatment with 
cryotherapy for screen positive patients. The evidence-based SAT 
approach has been implemented in low-resource settings around 
the world (10–12). Several South African studies have found the 
SAT approach cost-effective, safe, and efficacious in screening 
for and treating cervical dysplasia (13, 14). SAT procedures have 
been endorsed by multiple international organizations, including 
The American Congress of Obstetrics and Gynecology and The 
Royal College of Obstetricians and Gynecologists (15).
Following the success of the PEPFAR-funded SAT pilot 
program initiated by the Botswana-UPenn Partnership (BUP) in 
2009, the Botswana MOH endorsed VIA in 2011 as an additional 
screening modality, linked to same treatment visit cryotherapy. 
The first comprehensive national cervical cancer prevention 
strategic plan (2012–2016) incorporated the lessons learned 
from this pilot. The strategy calls for the dual use of VIA and 
Pap smear (use of either methods) for wider screening coverage 
for women aged 30–49 years (the highest at-risk group for pre-
cancer). Implementation of this strategy, in part, will be made 
possible by additional PEPFAR funding through the pink ribbon 
red ribbon (PRRR) initiative of the Bush Foundation. PRRR is 
a public/private partnership between the United States govern-
ment and private organizations for the prevention of breast and 
cervical cancer. With PRRR support, Botswana has set up dual 
VIA/cryotherapy services linked to colposcopy/loop electrical 
excisional procedure (LEEP) clinics in five facilities using the 
template developed through the SAT pilot. The LEEP clinics 
will also provide service for patients referred with abnormal Pap 
smear results. These five facilities are within the catchment area of 
80% of the at-risk women. The target is to screen around 40,000 
(combined Pa and VIA) each year. Current annual screening 
numbers are around 30,000 smears and 3500 VIA a year. Service 
is provided by nurses and non-specialized doctors at VIA and 
LEEP clinics respectfully. Quality assurance and mentoring is 
maintained by an expert team through monthly visits and review 
of cervical images from the clinics.
There is planning for future addition of HVP DNA point-of-
care testing as a primary screening method once it is available 
and affordable. This is because the HPV DNA testing’s sensitivity 
is more superior to both cytology and VIA testing, and there is 
possibility of using self-collected swabs for screening. The HPV 
screen positive patients will be provided SAT in the established 
clinics.
As Botswana’s cervical cancer-screening program evolves, 
robust histopathology services will play an integral role in the 
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successful management of women with pre-cancerous and 
cancerous disease of the cervix. Challenges surrounding the 
lack of availability of pathology services in sub-Saharan Africa, 
Botswana included, are numerous and impact negatively on 
patient care. These obstacles include inadequate infrastructure, 
limited personnel (pathologists and technicians), limited training 
opportunities, and poor funding for pathology services (16).
Fortunately, the MOH has recognized the need to substan-
tially improve the anatomic pathology infrastructure in order 
to support the SAT program and the rising burden of cancers 
in general. Since 2009, the volume of specimens has doubled 
in Botswana, in part due to the successes of the SAT program, 
but the lab infrastructure had also eroded due to equipment 
problems and lack of sufficient personnel. With consultative 
input and in-kind donations from external partners [American 
Society for Clinical Pathologists (ASCP), BUP, and Botswana 
Oncology Global Outreach (BOTSOGO)], the MOH devel-
oped a comprehensive plan to expand capacity and decrease 
delays. In the past year, the National Heath Laboratory has 
installed an automated tissue processor and slide-stainer and 
tripled the number of functioning microtomes, eliminating 
the several week backlog resulting from a scarcity of histol-
ogy technicians and insufficient equipment. Additionally, 
the laboratory has installed an automated high-throughput 
slide scanner to enable telepathology as a strategy to address 
the shortage of pathologists in Botswana. The University of 
Botswana initiated a pathology residency program in January 
2013 and these residents will further expand the pool of quali-
fied pathologists. Finally, during periods of extended backlog, 
the MOH has utilized the private sector to expedite timely 
pathology results.
CeRviCAL CANCeR vACCiNATiON
Cervical cancer will remain as a difficult problem unless an effec-
tive HPV vaccine program is introduced for primary prevention 
(17)3. To this end, the Botswana MOH has added nationwide 
HPV vaccination of 9- to 13-year-old girls, about 10% of female 
population, to the current cervical cancer prevention efforts. A 
comprehensive HPV vaccination implementation plan for the 
national HPV vaccine roll out in 2015, funded by government 
of Botswana, using vaccine doses at a negotiated price from the 
manufacturer, has been completed and will be operationalized 
through the MOH’s Expanded Program for Immunization (EPI). 
Two doses of quadrivalent vaccination will be given to girls only. 
The target group in the first year will be all girls in standards/
grades 5–7 (last 3 years in primary school), and all 9–13 years old 
for girls not in school. In subsequent years, the vaccination will 
be for grade 5 girls in school and 9-year-old out-of-school girls 
(about 24,000 girls, about 2% of the female population, which 
should be a manageable number). The vaccination campaign will 
be conducted twice a year. The first dose was given the week of 
February 23rd 2015 and the second dose will be given within 
6–12 months. During vaccination weeks, vaccination is carried 
out in all public and private schools around the country, and the 
local clinics cater to the out-of-school girls.
Built into this geographic expansion and intensification 
of cervical cancer prevention is the aim of collecting quality 
data that can be used to evaluate the program at the end of 
the strategy period (2016). Furthermore, these data will allow 
locally relevant evidence to inform the second comprehensive 
cervical cancer prevention strategy document for the period 
of 2017–2021.
CeRviCAL CANCeR TReATMeNT
Even if these prevention interventions were implemented at scale 
today in Botswana, they would not have impact on the large bur-
den of cervical cancer for 10–20 years. It is, thus, vital that efforts 
also prioritize earlier detection and treatment of invasive cancer.
The majority of patients in Botswana present with locally 
advanced disease at diagnosis (1) when the primary treatment 
includes radiation therapy and cisplatin-based chemotherapy, 
rather than surgery (18). There are no gynecological oncologists 
in Botswana. Patients suspected of having cervical cancer are 
generally referred to gynecology for biopsy and pathological 
confirmation. A baseline evaluation is performed, including 
routine laboratories, chest x-ray, and renal ultrasound, if there is 
a concern for hydronephrosis. If the disease is locally advanced, 
the Botswana government sponsors patients to receive radiation 
therapy (external beam and brachytherapy) at Gaborone Private 
Hospital (GPH), the only radiation facility currently in the 
country.
For an estimated population of 2 million, there is a single 
radiation oncology facility in Botswana with one linear accelera-
tor and three radiation oncologists, located at the GPH which, 
although private, sees and treats 95% of the patients diagnosed 
with cervical cancer from public hospitals in the entire country 
(19, 20). Approximately 65 patients per day are treated at GPH 
on a single machine (19) and about 200 cervical cancer patients 
are treated per year at GPH with chemoradiation. Brachytherapy, 
internal radiation crucial to treatment of cervical cancer, was 
initiated at GPH in 2012 (21). For cervical cancer, unlike other 
solid malignancies in Botswana, all aspects of care, including 
chemotherapy and radiation, are delivered at GPH. Over 95% of 
patients treated at GPH are referred from government hospitals. 
Although the government covers all aspects of their treatment 
at GPH, this “public guarantee” runs out on the last day of their 
treatment. As a result, outcomes of treatment, including effective-
ness and toxicities, are currently unknown as no routine follow-
up care is performed.
The MOH recognizes the importance of developing a well-
coordinated multidisciplinary cervical cancer care program. 
However, currently, the system is fragmented with large distances 
and barriers to communication between diagnostic facilities, 
pathology laboratories, and the single comprehensive treatment 
center. Moreover, there are no provisions made in the current 
system for post-treatment follow-up of patients. As part of the 
University of Botswana Academic Hospital currently under con-
struction, a multidisciplinary cancer center in the public-sector is 
expected to open, including pathology, and radiation, gynecologi-
cal, and medical oncology services. Recently, a multidisciplinary 
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gynecological oncology clinic has been initiated at Princess 
Marina Hospital (PMH), the main public-sector tertiary hospital 
with specialty care, to improve gynecological oncology care in 
Botswana. A number of external partners [UPENN, BOTSOGO, 
National Cancer Institute (NCI), Center for Disease Control 
and Prevention, and MD Anderson Cancer Center] work to 
support the MOH and University of Botswana to improve cervi-
cal cancer care. Important among these many initiatives is the 
support of a US-trained radiation oncologist (Surbhi Grover) in 
Botswana, expansion of research capacity through a consortia 
grant focused on the immunology of HIV-associated cervical 
cancer (U54CA190158), ongoing bidirectional exchanges and 
mentorship to expand local clinical capacity, and maintenance of 
a research cohort permitting longitudinal assessment of cervical 
cancer outcomes.
CHALLeNGeS AND FUTURe DiReCTiONS
At present, there are limited data available regarding the stage 
of presentation for cervical cancer patients. A standardized 
and inter-linked hospital-based cancer registry representing 
various departments and hospitals that captures all cancer 
patients presenting at all stages of disease would be valuable. 
This registry would be crucial to understanding the burden 
of cancer in the country and guiding resource allocation, and 
would contribute toward national efforts to develop a national 
population-based cancer registry. Current MOH developments 
in this area include
- Publication and distribution of a standardized cancer (pas-
sive) reporting log book to major centers treating cancer
- Addition of cancer stage (TNM) to the metrics being col-
lected in the registry
- Training in May 2015 to cancer clinicians and registrars, and 
there is advocacy to expand the number of registrars who are 
conducting active reporting into the registry (currently, there 
are two for the entire country).
Based on pilot data from BUP, we know that patients undergo-
ing radiation therapy present mostly with stage IIB or higher dis-
ease, but we are unaware of both how many patients are presenting 
with early stage disease that may be treated in other gynecology 
facilities around the country, and also trends in disease stage at 
presentation. This information is crucial to understanding the 
impact of both screening and vaccination programs, especially 
as the screening programs are being expanded in an effort to 
downstage cervical cancers.
Patient education and community sensitization are crucial for 
timely diagnosis and treatment. Expansion of the screening pro-
gram provides a unique opportunity for patient education regard-
ing the goals of screening, signs of disease, and the opportunities 
to access care if disease is suspected. These education efforts will 
also help with delays in treatment and may lead to fewer cases of 
advanced stage at diagnosis.
Based on pilot data from BUP (1), we know that over 60% of 
cervical cancer patients with advanced disease are HIV positive. 
However, randomized studies that established the standard of care 
for cervical cancer did not include any patients with HIV. We need 
additional studies to understand the outcomes of cervical cancer 
patients in Botswana, and to validate the current standard of care 
or establish a new standard of care for this HIV-infected patient.
Based on pilot data, the median time from diagnosis to treat-
ment is about 4–5 months (1). Currently, it is unclear why that 
may be, although potential hypotheses include the distance from 
treatment center, poor healthcare systems, easier access to tradi-
tional healers, financial opportunity costs, limited cancer aware-
ness, and cancer stigma. Better understanding of the relevant 
contributors to delay will be crucial to improving cancer-related 
mortality. Similarly, identifying and addressing the barriers to 
continue follow-up is essential for early detection and interven-
tion for disease recurrence and management of treatment side 
effects. This comprehensive approach will lead to both improved 
patient outcomes and quality of life.
Lack of access to trained human resources is another challenge. 
Appropriate cancer care requires adequate resources in pathol-
ogy, radiology, oncology nursing, and specifically for radiation, 
therapy-medical physicists, radiation therapy technicians, and 
dosimetrists. MOH is aware of these challenges and is making 
efforts toward tackling these issues with various domestic and 
international stakeholders.
In conclusion, the national cervical cancer screening and 
vaccination programs have the potential to positively impact 
the plight of cervical cancer patients in Botswana. Several 
efforts are underway to improve treatment for women with 
cervical cancer. Moreover, the experience and data obtained 
from these efforts can inform ongoing as well as future domestic 
and international collaborations that will expand capacity to 
prevent, treat, and study cervical cancer. We hope that some 
of the lessons learned in Botswana can be used in the future to 
develop a sustainable and comprehensive oncology program in 
other countries as well.
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